Orphagen Pharmaceuticals Secures Significant NIH Funding
Orphagen Pharmaceuticals, a leading biotech company focused on revolutionizing drug development in the field of orphan nuclear receptors, recently announced it has received an award of up to $1.7 million from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This grant, awarded through the Small Business Innovation Research (SBIR) program, is aimed at supporting the preclinical development of OR-812, a novel small molecule and selective nuclear receptor antagonist.
Development of OR-812: A Breakthrough in Treatment
OR-812 is designed to be an innovative oral therapy for treating ulcerative colitis and Crohn’s disease, both of which are forms of inflammatory bowel disease (IBD). According to Scott Thacher, Ph.D., the CEO of Orphagen, this funding recognizes the innovative preclinical research the company has conducted, particularly in characterizing retinoic acid receptor alpha (RAR?) as a key target in inhibiting autoimmune inflammation of the intestinal mucosa.
Addressing Autoimmune Inflammation
Dr. Thacher emphasized the potential of OR-812 to provide a new oral therapy alternative for IBD patients, a condition that currently sees a predominance of injectable treatments. He noted, "Our molecule offers a differentiated mechanism of action when compared to existing therapies, which is crucial for patients who struggle with the limitations of current treatment options."
The IBD Landscape and Current Treatment Challenges
With up to two million individuals affected by IBD in the United States alone, this chronic and debilitating condition significantly impacts the quality of life of those diagnosed. Current treatments, including monoclonal antibodies targeting TNF? and other pathways, have not provided sustained therapeutic benefits to many patients, which remains a pressing issue in the management of IBD.
Orphagen's Innovative Approach
Orphagen's research centers around the exploration of the nuclear receptor family, identified as a promising avenue for drug development in various critical health conditions. The investigation into the RAR? receptor is particularly noteworthy, given its pivotal role in the immune response within the gut. Studies indicate that RAR? antagonists like OR-812 can effectively block the induction of integrin ?4?7 and CCR9, both of which are vital in T cell migration to the intestinal mucosa during inflammatory responses.
Promising Preclinical Findings
Notable findings from research conducted in collaboration with Professor Casey Weaver, a leading expert in mucosal immunology, show that RAR? antagonists can significantly inhibit the expression of ?4?7 in intestinal T cells. This inhibition has been linked with a reduction in the inflammatory T cell accumulation in models that mimic IBD conditions. Additionally, preliminary safety analyses suggest a robust safety profile for OR-812, which could pave the way for effective clinical applications.
Growing Need for New IBD Therapies
As the global incidence of IBD continues to rise, the need for innovative therapies has never been more urgent. Dr. Weaver pointed out that selectively targeting RAR? to block retinoic acid action represents one of the promising strategies in addressing this demand.
About Inflammatory Bowel Disease
IBD encompasses a range of disorders, including Crohn’s disease and ulcerative colitis, characterized by chronic gastrointestinal inflammation. Ulcerative colitis leads to a continuous stretch of inflammation within the colon, with many patients suffering frequent debilitating flares. Conversely, Crohn’s disease can affect any area along the gastrointestinal tract, often leading to more complex clinical scenarios and challenges in treatment.
Overview of Orphagen Pharmaceuticals
Orphagen Pharmaceuticals is dedicated to harnessing the potential of orphan nuclear receptors. The company focuses on developing small molecule ligands that target these largely unexplored areas, enhancing therapeutic options for autoimmune diseases and oncology. Their advancing programs, including OR-812 for IBD, reflect their strong commitment to innovative drug discovery.
Frequently Asked Questions
What is OR-812?
OR-812 is a small molecule drug being developed by Orphagen Pharmaceuticals targeting retinoic acid receptor alpha (RAR?) for treating inflammatory bowel disease.
What was the amount awarded by the NIH?
The NIH awarded Orphagen Pharmaceuticals up to $1.7 million to support the development of OR-812.
What conditions does OR-812 aim to treat?
OR-812 is aimed at treating ulcerative colitis and Crohn's disease, which are forms of inflammatory bowel disease (IBD).
How does OR-812 differ from current IBD therapies?
Unlike many current therapies that are injectable, OR-812 is being developed as a novel oral medication, which offers a differentiated mechanism of action from existing treatments.
Why is RAR? a target for treatment?
RAR? plays a crucial role in immune responses in the gut, and inhibiting its action can significantly affect the inflammatory processes associated with IBD.
